Cardiol Therapeutics Company Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.

Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.

It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

Country	Canada
Founded	2017
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	David Elsley

Contact Details

Address: 2265 Upper Middle Road East Oakville, Ontario L6H 0G5 Canada
Phone	289 910 0850
Website	cardiolrx.com

Stock Details

Ticker Symbol	CRDL
Exchange	Toronto Stock Exchange
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	CAD
ISIN Number	CA14161Y2006
SIC Code	2836

Key Executives

Name	Position
David G. Elsley MBA	President, Chief Executive Officer and Director
Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA	Chief Financial Officer, Corporate Secretary and Director
Bernard Lim B.Sc.	Chief Operating Officer
Dr. Andrew Warwick Hamer M.D.	Chief Medical Officer and Head of Research & Development
Trevor Burns	Investor Relations
John A. Geddes BSCPT, MBA	Vice President of Corporate Development